Suggested remit: To appraise the clinical and cost effectiveness of inebilizumab within its marketing authorisation for treating neuromyelitis optica spectrum disorders.
Status In progress
Decision Selected
Process STA 2018
ID number 1529

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
03 April 2020 In progress. Topic is in progress
03 April 2020 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Inebilizumab within its marketing authorisation for reducing the risk of attacks and worsening of disability in patients with neuromyelitis optica spectrum disorders. Please note that following advice received from the company, further information regarding the timelines for this appraisal will be available in due course.
02 September 2019 (14:00) Scoping workshop (Manchester)
18 July 2019 - 15 August 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual